Prescription medicine
Atogepant Brand names: Qulipta
Atogepant (Qulipta) is a prescription medicine with an FDA approval on record since 2021. No generic is listed; pharmacies paid $38.36 per Qulipta 10 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the atogepant FDA label on DailyMed (effective September 30, 2025, AbbVie Inc.); the NDA 215206 record on Drugs@FDA; every atogepant label on DailyMed.
Highlights of the record
FDA label of September 30, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageQULIPTA is indicated for the preventive treatment of migraine in adults.
Forms and strengths
- 10 mg
- 30 mg
- 60 mg
Tablet.
On the market
- Earliest approval on file
- September 28, 2021 Qulipta, Abbvie; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- February 27, 2043 Qulipta tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $38.36 per tablet Qulipta 10 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 6,568 through July 30, 2026
What is atogepant used for?
From the label: indications and usageQULIPTA is indicated for the preventive treatment of migraine in adults. QULIPTA is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults.
Conditions named in the indications of atogepant's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Calcitonin Gene-related Peptide Receptor Antagonist.
Source: FDA drug label (Qulipta), AbbVie Inc., effective September 30, 2025 (SPL set 8c8ab8f4-32bd-497a-befa-70c8a51d8d52), via openFDA; the full label on DailyMed
Is there a generic for atogepant (Qulipta)?
No generic atogepant is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 9 patents for Qulipta tablets: the compound patent runs to September 28, 2035, and the last listed entry to February 27, 2043. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2021 earliest approval on file
- 2043 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for atogepant (Qulipta)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $38.36 per Qulipta 10 mg tablet, up 5% from $36.59 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Qulipta 10 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Qulipta 10 mg tablet | Brand | $38.36 per tablet | $1,150.75 | +5% |
| Qulipta 30 mg tablet | Brand | $38.38 per tablet | $1,151.33 | +5% |
| Qulipta 60 mg tablet | Brand | $38.45 per tablet | $1,153.48 | +5% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the atogepant label say about other medicines?
The atogepant label names 3 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Itraconazole | drug interactions | Coadministration of QULIPTA with itraconazole, a strong CYP3A4 inhibitor, resulted in a significant increase in exposure of atogepant in healthy subjects [see Clinical Pharmacology ( 12.3 )]. |
| Rifampin | drug interactions | Coadministration of QULIPTA with steady-state rifampin, a strong CYP3A4 inducer and OATP1B1 and OATP1B3 inhibitor, resulted in a significant decrease in exposure of atogepant in healthy subjects [see Clinical Pharmacology ( 12.3 )]. |
| Topiramate | drug interactions | Coadministration of QULIPTA with steady-state topiramate, a weak CYP3A4 inducer, resulted in decreased exposure of atogepant in healthy subjects [see Clinical Phar macology ( 12.3 )]. |
Source: FDA drug label (Qulipta), AbbVie Inc., effective September 30, 2025 (SPL set 8c8ab8f4-32bd-497a-befa-70c8a51d8d52), via openFDA; the full label on DailyMed
What do FAERS reports show for atogepant?
The FDA Adverse Event Reporting System holds 6,568 reports that list atogepant among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 76 are coded as a death and 590 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2023 (1,716, against a median of 8 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as atogepant?
12 other medicines are given the same way (oral) and in the same FDA class as atogepant or labeled mainly for the same use (migraine), the same class first. Migraine lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Ubrogepant | Migraine | none listed | $109.11 per tablet 100 mg tablet | No current entry |
| Rimegepant | Migraine | none listed | $128.67 per tablet 75 mg tablet | No current entry |
| Sumatriptan | Migraine | 22 labelers | $0.302 per tablet 50 mg tablet | No current entry |
| Rizatriptan | Migraine | 25 labelers | $0.335 per tablet 10 mg tablet | No current entry |
| Zolmitriptan | Migraine | 18 labelers | $1.02 per tablet 2.5 mg tablet | No current entry |
| Eletriptan | Migraine | 10 labelers | $1.75 per tablet 40 mg tablet | No current entry |
| Naratriptan | Migraine | 4 labelers | $1.08 per tablet 2.5 mg tablet | No current entry |
| Almotriptan | Migraine | 3 labelers | $16.86 per tablet 12.5 mg tablet | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to atogepant
- 12 medicines for the same use
- Other calcitonin gene-related peptide receptor antagonists
- the pharmacologic class, with prices and generics
- Atogepant side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other